Post-Finasteride Syndrome: An Underestimated Phenomenon
DOI:
https://doi.org/10.17140/UAOJ-1-e002Keywords:
benign prostate hyperplasia (BPH), Food and Drug Administration (FDA), finasteride for androgenic alopecia (AGA), Information Management System (IMS), side effects of 5 alpha reductase inhibitors (5ARIs), androgenic alopecia (AGA)Abstract
With their increased popularity in the treatment of benign prostate hyperplasia (BPH), physicians are encountering with the side effects of 5 alpha reductase inhibitors (5ARIs) (finasteride and dutasteride) more often. Although reports regarding the persistence of these problems raise the concerns of physicians and BPH patients alike,1,2 annual 5ARI sales continue to increase, generating approximately half billion dollars in the United States, according to Information Management System (IMS) data.3 The United States Food and Drug Administration (FDA) approval of finasteride for androgenic alopecia (AGA) contributes to the 5ARI market and broaden the population who may suffer from side effects by decreasing the age span.4
References
Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011; 8(6): 1747-1753.
Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5 alpha-reductase inhibitors therapy: Per-sistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011; 8(3): 872-884. doi: 10.1111/j.1743-6109.2010.02157.x
Cassels A, Wright JM, Mintzes B, Jauca C. Direct-to-consumer advertising. Finasteride for male pattern hair loss. Can Fam Phy-sician. 2001; 47: 1751-1755. Web site. http://www.cfp.ca/content/47/9/1751.long. Accessed September 10, 2016
Post-Finasteride Syndrome: Overview. Post-Finasteride Syndrome Foundation Somerset, New Jersey 2016. Web site. http://www. pfsfoundation.org/post-finasteride-syndrome-overview/. Accessed September 10, 2016
Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 1994; 43(3): 284-294. doi: 10.1016/0090-4295(94)90068-X
I Motofei DR, Georgescu SR, Tampa M, et al. The post-finasteride syndrome after distinct doses/ affections. J Invest Dermatol. 2015; 135: S40. Web site. http://scholar.valpo.edu/psych_fac_pub/22/. Accessed September 10, 2016
Wessells H, Roy J, Bannow J, et al. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology. 2003; 61(3): 579-584. doi: 10.1016/S0090-4295(02)02401-9
Ganzer CA, Jacobs AR, Iqbal F. Persistent sexual, emotional, and cognitive impairment post-finasteride: A survey of men report-ing symptoms. Am J Mens Health. 2015; 9(3): 222-228. doi: 10.1177/1557988314538445 Urol Androl Open J Page e4
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Urology and Andrology (UA) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
